SAGE Sage Therapeutics Inc.

68.02
-2.44  -3%
Previous Close 70.46
Open 70.8
Price To Book 3.26
Market Cap 3,524,628,323
Shares 51,817,529
Volume 1,177,861
Short Ratio
Av. Daily Volume 1,357,595
Stock charts supplied by TradingView

NewsSee all news

  1. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  2. Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the

  3. Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

    Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington's Disease related cognitive impairment and potential for positive cognitive effects with SAGE-718 Sage Therapeutics

  4. Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder

    MOUNTAIN Study did not meet primary endpoint at Day 15 Statistical significance on HAM-D scale achieved at Days 3, 8 and 12; preliminary data from long-term follow-up suggest maintenance of effect on depressive

  5. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced March 19, 2018.
Brexanolone - SAGE-547 (202C)
Postpartum Depression - moderate
Phase 3 data did not meet primary endpoint - December 5, 2019.
SAGE-217 - MOUNTAIN
Major Depressive Disorder (MDD)
Phase 3 data met primary endpoint - January 7, 2019.
SAGE-217
Postpartum depression (PPD)
Phase 3 data released November 9, 2017. Primary endpoint met.
Brexanolone - SAGE-547 (202B)
Postpartum Depression (Severe)
Phase 3 data released September 12, 2017 - primary endpoint not met.
SAGE-547
SRSE
Phase 3 data due 2020.
SAGE-217 - RAINFOREST
Insomnia
Phase 2 Part A data July 24, 2019 noted MADRS score of 15.5 points at Day 15 (n=23; p<0.0001) - secondary endpoint.
SAGE-217 - ARCHWAY
Bipolar depression
Phase 2 trial planned.
SAGE-718
Huntington's disease
Phase 2 trial to be initiated 4Q 2019.
SAGE-324
Essential tremor
Phase 3 data due 2020.
SAGE-217 - SHORELINE
Major Depressive Disorder (MDD)
Phase 3 dosing commenced in 3Q 2019
SAGE-217 - REDWOOD
Major Depressive Disorder

Latest News

  1. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  2. Sage Therapeutics to Present at J.P. Morgan Healthcare Conference on Monday, January 13, 2020

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the

  3. Sage Therapeutics Announces Planned Progression of SAGE-718 to Phase 2 in Huntington's Disease and Presentations at the 2019 Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

    Three poster presentations highlight the role of NMDA receptor dysfunction in Huntington's Disease related cognitive impairment and potential for positive cognitive effects with SAGE-718 Sage Therapeutics

  4. Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder

    MOUNTAIN Study did not meet primary endpoint at Day 15 Statistical significance on HAM-D scale achieved at Days 3, 8 and 12; preliminary data from long-term follow-up suggest maintenance of effect on depressive

  5. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  6. Sage Therapeutics Announces Third Quarter 2019 Financial Results and Highlights Pipeline and Business Progress

    ZULRESSO™ (brexanolone) CIV injection revenues of $1.5M in third quarter Enrollment completed in SAGE-217 Phase 3 MOUNTAIN and SHORELINE studies with topline data expected in 4Q 2019 and 2020, respectively Planning

  7. Sage Therapeutics to Present at the Stifel 2019 Healthcare Conference

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the

  8. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  9. Sage Therapeutics to Report Third Quarter 2019 Financial Results on Tuesday, November 12, 2019

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced it will

  10. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  11. Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Sage Therapeutics, Inc. (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced

  12. Sage Therapeutics Announces the New England Journal of Medicine Publishes Data from Phase 2 Trial with SAGE-217 in Major Depressive Disorder

    Results from pivotal trial showed treatment with SAGE-217 resulted in rapid, clinically meaningful improvement in major depressive disorder (MDD) symptoms across multiple measures and time points SAGE-217 is currently

  13. Sage Therapeutics to Present at the Morgan Stanley Global Healthcare Conference

    Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that the